Overview

Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy Subjects

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I study to assess the drug-drug interaction of XZP-3287 and Clarithromycin/Rifampicin. The study also evaluates the pharmacokinetic and tolerability of XZP-3287 in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Xuanzhu Biopharmaceutical Co., Ltd.
Treatments:
Clarithromycin
Rifampin